{"id":"folfox-xelox-capecitabine","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"30-40","effect":"Nausea/vomiting"},{"rate":"20-30","effect":"Peripheral neuropathy"},{"rate":"20-30","effect":"Anemia"},{"rate":"15-25","effect":"Mucositis"},{"rate":"10-20","effect":"Hand-foot syndrome (capecitabine)"}]},"_chembl":{"chemblId":"CHEMBL1773","moleculeType":"Small molecule","molecularWeight":"359.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFOX combines 5-fluorouracil (5-FU), leucovorin, and oxaliplatin; XELOX substitutes capecitabine (an oral 5-FU prodrug) for intravenous 5-FU. 5-FU inhibits thymidylate synthase, disrupting DNA synthesis, while oxaliplatin creates platinum-DNA adducts causing cross-linking and apoptosis. These are standard cytotoxic chemotherapy regimens used in colorectal and gastric cancers.","oneSentence":"FOLFOX/XELOX regimens are chemotherapy combinations that inhibit thymidylate synthase and cause DNA damage to kill rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:54.300Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Adjuvant treatment of stage III colorectal cancer"},{"name":"Gastric cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT06346197","phase":"PHASE3","title":"Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2025-12-08","conditions":"Gastric Cancer, MSI-H, Metastatic Cancer","enrollment":132},{"nctId":"NCT05702229","phase":"PHASE2","title":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-01-16","conditions":"Gastric Cancer","enrollment":163},{"nctId":"NCT04495088","phase":"PHASE3","title":"Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Ralf Hofheinz","startDate":"2020-09-30","conditions":"Rectal Cancer","enrollment":550},{"nctId":"NCT07328009","phase":"PHASE2","title":"A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-25","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":350},{"nctId":"NCT07241247","phase":"PHASE4","title":"Evaluation the of Role of Vitamin D Supplement on Tumor Response, Inflammation and Apoptosis in Patients With Stage II or III Colorectal Cancer Receiving Chemotherapy.","status":"COMPLETED","sponsor":"Tanta University","startDate":"2024-07-31","conditions":"Vitamin D on Tumor Response and Inflammatory Markers, Colo-rectal Cancer","enrollment":44},{"nctId":"NCT03904043","phase":"NA","title":"Non-Operative Management and Early Response Assessment in Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-07-01","conditions":"Adenocarcinoma of the Lower Rectum","enrollment":63},{"nctId":"NCT02872116","phase":"PHASE3","title":"Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-10-12","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma","enrollment":2031},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT07025174","phase":"PHASE2","title":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-06-01","conditions":"Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer","enrollment":60},{"nctId":"NCT04380337","phase":"PHASE2","title":"Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer","status":"COMPLETED","sponsor":"Stanford University","startDate":"2020-05-21","conditions":"Rectal Cancer","enrollment":38},{"nctId":"NCT03662659","phase":"PHASE2","title":"An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-10-16","conditions":"Gastric Cancer, Cancer of the Stomach, Esophagogastric Junction","enrollment":274},{"nctId":"NCT06475352","phase":"PHASE2","title":"Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-01-20","conditions":"Digestive Cancer, Colorectal Cancer","enrollment":400},{"nctId":"NCT06758830","phase":"PHASE2, PHASE3","title":"Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","status":"RECRUITING","sponsor":"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos","startDate":"2025-01-07","conditions":"Rectal Cancer, Total Neoadjuvant Treatment, Neoadjuvant Therapy","enrollment":400},{"nctId":"NCT06547385","phase":"PHASE1","title":"Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-01-13","conditions":"Colorectal Cancer","enrollment":40},{"nctId":"NCT05394740","phase":"PHASE1, PHASE2","title":"Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2022-06-06","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":30},{"nctId":"NCT06322147","phase":"","title":"Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-06-01","conditions":"Colon Cancer","enrollment":50},{"nctId":"NCT03485027","phase":"PHASE2","title":"Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2018-01-24","conditions":"Metastatic Colorectal Cancer, Chemotherapy Effect","enrollment":43},{"nctId":"NCT06121700","phase":"PHASE2","title":"Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-01-01","conditions":"Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer","enrollment":55},{"nctId":"NCT06123455","phase":"PHASE2","title":"Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Tang-Du Hospital","startDate":"2023-08-01","conditions":"Gastric Cancer","enrollment":60},{"nctId":"NCT06115174","phase":"PHASE4","title":"Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-11-01","conditions":"Metastatic Colorectal Carcinoma","enrollment":44},{"nctId":"NCT00958737","phase":"PHASE3","title":"Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer","status":"UNKNOWN","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2009-05-12","conditions":"Colorectal Cancer","enrollment":2000},{"nctId":"NCT03957733","phase":"PHASE2, PHASE3","title":"Phase II/III Study to Assess the Efficacy of Neoadjuvant Consolidation Chemotherapy in Rectal Cancer Patients.","status":"UNKNOWN","sponsor":"King Abdullah Medical City","startDate":"2017-11-23","conditions":"Rectal Cancer","enrollment":338},{"nctId":"NCT05074966","phase":"PHASE3","title":"The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-09-06","conditions":"Colo-rectal Cancer","enrollment":314},{"nctId":"NCT02934464","phase":"PHASE3","title":"Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2016-12","conditions":"Stomach Neoplasms","enrollment":280},{"nctId":"NCT03031444","phase":"PHASE2, PHASE3","title":"Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-01","conditions":"Colorectal Cancer Stage IV, Metastasis","enrollment":135},{"nctId":"NCT02114359","phase":"PHASE3","title":"Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-02","conditions":"Gastric Cancer","enrollment":111},{"nctId":"NCT04303429","phase":"PHASE3","title":"Adjuvant Chemotherapy in High Risk Stage II Colon Cancer","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2020-08","conditions":"Stage II Colon Cancer, Adjuvant Chemotherapy","enrollment":962},{"nctId":"NCT01490996","phase":"PHASE1, PHASE2","title":"Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2012-02","conditions":"Colonic Cancer, Metastasis","enrollment":41},{"nctId":"NCT04198051","phase":"NA","title":"The Clinical Study of Adjuvant Chemotherapy on Intestinal and Urethral Flora in Patients With Gastric and Colon Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2019-12-20","conditions":"Gastric Cancer, Colon Cancer","enrollment":120},{"nctId":"NCT00551213","phase":"PHASE2","title":"A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11-21","conditions":"Colorectal Cancer","enrollment":67},{"nctId":"NCT03532711","phase":"","title":"Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2012-01-01","conditions":"Metastatic Colorectal Cancer, Chemotherapy Effect, Biomarker","enrollment":264},{"nctId":"NCT01308086","phase":"PHASE3","title":"Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer","status":"UNKNOWN","sponsor":"Hellenic Oncology Research Group","startDate":"2010-10","conditions":"CRC","enrollment":2000},{"nctId":"NCT02063412","phase":"","title":"Nursing and Pharmacy Care Between Capecitabine and 5-Fluoruracil Regimens","status":"WITHDRAWN","sponsor":"Vivian Wing Yan Lee","startDate":"2013-08","conditions":"Gastric Cancer","enrollment":""},{"nctId":"NCT00399035","phase":"PHASE3","title":"Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-11","conditions":"Metastatic Colorectal Cancer","enrollment":1254},{"nctId":"NCT02590367","phase":"PHASE2, PHASE3","title":"Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Jiangsu Province Hospital of Traditional Chinese Medicine","startDate":"2015-08","conditions":"Peripheral Neuropathy","enrollment":64},{"nctId":"NCT01077739","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-07","conditions":"Colorectal Cancer","enrollment":75},{"nctId":"NCT00646607","phase":"PHASE3","title":"FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer","status":"COMPLETED","sponsor":"Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","startDate":"2007-06","conditions":"Colon Cancer","enrollment":3756},{"nctId":"NCT01748851","phase":"PHASE3","title":"XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)","status":"TERMINATED","sponsor":"Dong-A University Hospital","startDate":"2012-12","conditions":"Gastric Carcinoma Stage IV","enrollment":42},{"nctId":"NCT01157052","phase":"PHASE1","title":"Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients","status":"UNKNOWN","sponsor":"AHS Cancer Control Alberta","startDate":"2015-01","conditions":"Neoplasms, Colorectal, Colorectal Cancer, Colorectal Carcinoma","enrollment":15},{"nctId":"NCT01763450","phase":"PHASE2","title":"Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2012-09","conditions":"Liver Metastases, Colorectal Cancer","enrollment":100},{"nctId":"NCT01679327","phase":"PHASE2","title":"Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2012-03","conditions":"Colorectal Cancer","enrollment":100},{"nctId":"NCT01453257","phase":"PHASE2","title":"Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients","status":"COMPLETED","sponsor":"Grupo Hospital de Madrid","startDate":"2009-10","conditions":"Progression Free Survival","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FOLFOX/XELOX/Capecitabine","genericName":"FOLFOX/XELOX/Capecitabine","companyName":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","companyId":"shanghai-general-hospital-shanghai-jiao-tong-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFOX/XELOX regimens are chemotherapy combinations that inhibit thymidylate synthase and cause DNA damage to kill rapidly dividing cancer cells. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colorectal cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}